Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: September 15, 2005
Last updated: November 17, 2011
Last verified: November 2011
To evaluate the immunogenicity, reactogenicity and safety of Hepatyrix when compared to the concomitant administration of Typherix and Havrix, and when compared to the administration of monovalent vaccines, Havrix or Typhim Vi. Furthermore, the study will evaluate the persistence of anti-Vi and anti-HAV antibodies up to 36 months after administration of the first dose of the study vaccine.

Condition Intervention Phase
Hepatitis B
Hepatitis A
Biological: Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase III, Open, Randomized, Multicentric Study to Compare the Reactogenicity and Immunogenicity of GSK Bios' Combined Vi Polysaccharide Typhoid Vac and Inactivated Hepatitis A Vac, to That Elicited by GSK Bios' Hepatitis A Vac, Admin Singly or Concomitantly With GSK Bios' Vi Polysaccharide Vac

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Anti-Vi seropositivity rates (i.e., percentage of subjects with anti-Vi antibody titres > or = 150 EL.U/ml) at Month 1 after administration of study vaccine (Comparison of Hepatyrix versus concomitant Havrix+Typherix and Hepatyrix versus Typhim Vi). [ Designated as safety issue: No ]
  • Anti-HAV seropositivity rates (i.e., percentage of subjects with anti-HAV antibody titres >or = 15 mIU/ml) at Month 1 after administration of study vaccine, (Comparison of Hepatyrix versus concomitant Havrix+Typherix and Hepatyrix versus Havrix). [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Anti-Vi seropositivity rates at Day 14, Month 6 and Month 7 and GMTs at Day 14, Month 1, Month 6 and Month 7 after administration of study vaccine. [ Designated as safety issue: No ]
  • Anti-HAV seropositivity rates at Day 14, Month 6 and Month 7 and GMTs at Day 14, Month 1, Month 6 and Month 7 after administration of study vaccine. [ Designated as safety issue: No ]
  • Anti-Vi and anti-HAV seropositivity rates and GMTs at Months 12, 24, 36 after administration of study vaccine. [ Designated as safety issue: No ]
  • Occurrence and intensity of solicited local symptoms after vaccination (Day 0 to 4). [ Designated as safety issue: No ]
  • Occurrence, intensity and relationship of solicited general symptoms after vaccination (Day 0 to 4). [ Designated as safety issue: No ]
  • Occurrence, intensity and relationship to vaccination of unsolicited signs and symptoms after vaccination (Day 0 to 30). [ Designated as safety issue: No ]
  • Occurrence, intensity and relationship to vaccination of serious adverse events (SAEs) during the study period and during the follow-up period up to Months 12, 24 and 36 after administration of study vaccine. [ Designated as safety issue: No ]

Enrollment: 1034
Study Start Date: May 2002
Study Completion Date: November 2005
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)
Detailed Description:
Compare the reactogenicity & immunogenicity of GSK Biologicals' combined Vi polysaccharide typhoid vaccine & inactivated hepatitis A vaccine, Hepatyrix, to that elicited by GSK Biologicals' hepatitis A vaccine, Havrix administered singly or concomitantly with GSK Biologicals' Vi polysaccharide vaccine, Typherix, & to that elicited by Aventis Pasteur's monovalent Vi polysaccharide vaccine, Typhim Vi, administered intramuscularly to healthy subjects aged 18-65 yrs.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion criteria

  • Written informed consent will be obtained from the subject prior to entry into the study.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Seronegative for anti-HAV antibodies.
  • If the subject is female, she must be of non-childbearing potential, i.e., either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (e.g., intrauterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam; Norplant® or DepoProvera®) for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.
  • Subjects having received the study vaccines 36 months earlier.

Exclusion criteria

  • Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. (For corticosteroids, this will mean prednisone, or equivalent, >or = 0.5 mg/kg/day. Inhaled and topical steroids are allowed.).
  • Planned administration/Administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s).
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • History of chronic alcohol consumption and/or intravenous drug abuse.
  • Previous vaccination against hepatitis A.
  • Previous vaccination against typhoid fever.
  • History of hepatitis A.
  • Previous diagnosis, confirmed by a physician, of Salmonella typhi infection.
  • History of non-response to hepatitis A and or typhoid vaccine.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e., axillary temperature < 99.5 °F (37.5 °C)
  • Female planning to become pregnant during the primary study period (up Month 7).
  • Pregnant or lactating female.
  • Planned travel to areas of high endemicity for hepatitis A and/ or typhoid fever during the primary study period (up Month 7).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00197249

Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT00197249     History of Changes
Other Study ID Numbers: 270362/006  270362/007 (Ext. Mth12)  270362/008 (Ext. Mth24)  270362/009 (Ext. Mth36) 
Study First Received: September 15, 2005
Last Updated: November 17, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by GlaxoSmithKline:
Hepatitis A & B

Additional relevant MeSH terms:
Hepatitis A
Hepatitis B
Typhoid Fever
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Salmonella Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections processed this record on August 25, 2016